[
  {
    "id": "seq-FMC63-001",
    "text_summary": "FMC63 is the most widely used anti-CD19 scFv in FDA-approved CAR-T therapies including tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, and lisocabtagene maraleucel. It binds a membrane-proximal epitope on CD19 with sub-nanomolar affinity (Kd ~0.3 nM) and demonstrates excellent stability in single-chain format. The VH-linker-VL orientation with a (G4S)3 flexible linker is standard across approved constructs.",
    "construct_name": "Tisagenlecleucel (Kymriah)",
    "target_antigen": "CD19",
    "scfv_clone": "FMC63",
    "binding_affinity_kd": "0.3 nM",
    "heavy_chain_vregion": "VH derived from murine hybridoma FMC63. Framework regions are murine IgG1-kappa germline. CDR-H3 is 12 residues with a characteristic aromatic-rich loop (Tyr-Tyr-Gly-Ser-Ser-Tyr motif) contributing to high-affinity CD19 engagement.",
    "light_chain_vregion": "VL kappa chain with 9-residue CDR-L3. The light chain contributes to epitope recognition through CDR-L1 and CDR-L3 contacts with the CD19 extracellular domain. VL framework shows stable folding independent of constant region.",
    "framework": "murine IgG1 VH/VK",
    "species_origin": "murine",
    "immunogenicity_risk": "moderate",
    "structural_notes": "Crystal structure of FMC63 scFv bound to CD19 ECD reveals contacts with both Ig-like domains of CD19. The epitope is conformational, spanning residues 100-280 of CD19. VH contributes ~65% of the buried surface area. Anti-drug antibodies (ADA) detected in ~5% of patients in ELIANA trial."
  },
  {
    "id": "seq-FMC63-002",
    "text_summary": "The FMC63 scFv as implemented in axicabtagene ciloleucel (Yescarta) uses a CD28 transmembrane and costimulatory domain rather than the 4-1BB domain used in Kymriah. Despite identical scFv sequences, the CD28 costimulatory domain produces a more rapid but less durable T-cell response. The construct uses a GM-CSF signal peptide and CD8alpha hinge.",
    "construct_name": "Axicabtagene ciloleucel (Yescarta)",
    "target_antigen": "CD19",
    "scfv_clone": "FMC63",
    "binding_affinity_kd": "0.3 nM",
    "heavy_chain_vregion": "Identical VH to Kymriah FMC63. CDR-H1 (GYTFTSY), CDR-H2 (YPGNGD), CDR-H3 (RDDYYGSSSYV) sequences are conserved across all FDA-approved FMC63 constructs. Framework 3 region contains a stabilizing disulfide between Cys22 and Cys92.",
    "light_chain_vregion": "Identical VL kappa to Kymriah FMC63. CDR-L1 (RASQDISKYLN), CDR-L2 (HTSRLHS), CDR-L3 (QQGNTLPYT). VL contributes critical contacts via CDR-L1 Asp residue that forms a salt bridge with CD19 Lys144.",
    "framework": "murine IgG1 VH/VK",
    "species_origin": "murine",
    "immunogenicity_risk": "moderate",
    "structural_notes": "Retroviral vector delivery (gamma-retrovirus) in Yescarta vs. lentiviral in Kymriah. The scFv is presented in VL-linker-VH orientation in some constructs. CD28 hinge is shorter than CD8alpha hinge, positioning the scFv closer to the T-cell membrane."
  },
  {
    "id": "seq-SJ25C1-003",
    "text_summary": "SJ25C1 is an alternative murine anti-CD19 scFv originally developed at St. Jude Children's Research Hospital. It recognizes a partially overlapping but distinct epitope on CD19 compared to FMC63, providing an alternative binder for patients who develop resistance to FMC63-based CARs. The clone has been extensively used in early clinical studies at Memorial Sloan Kettering.",
    "construct_name": "SJ25C1-based anti-CD19 CAR",
    "target_antigen": "CD19",
    "scfv_clone": "SJ25C1",
    "binding_affinity_kd": "0.6 nM",
    "heavy_chain_vregion": "VH from murine IgG1 hybridoma SJ25C1. CDR-H3 is 14 residues long with a beta-hairpin conformation. Framework regions show 78% homology to human VH3 germline. The H3 loop contains a conserved Trp-Asp motif critical for antigen contact.",
    "light_chain_vregion": "VL kappa chain with a 10-residue CDR-L3 containing a Pro-Trp motif. CDR-L1 is longer (17 residues) than FMC63 CDR-L1, creating a broader antigen contact surface. VL stability is comparable to FMC63 in thermal denaturation studies (Tm ~62C).",
    "framework": "murine IgG1 VH/VK",
    "species_origin": "murine",
    "immunogenicity_risk": "moderate",
    "structural_notes": "SJ25C1 binds CD19 with a different approach angle than FMC63, contacting the membrane-distal Ig domain more extensively. Competition binding assays show partial overlap with FMC63 epitope. Used in 19-28z CAR construct at MSKCC with CD28 costimulation (Brentjens et al., Blood 2011, PMID:21471522)."
  },
  {
    "id": "seq-CAT19-004",
    "text_summary": "CAT-19 is a humanized anti-CD19 scFv developed to reduce immunogenicity risk associated with murine-derived binders. CDR grafting from FMC63 onto human VH3-23/VK1-39 acceptor frameworks preserved binding affinity while reducing predicted T-cell epitopes. Early clinical data from the AUTO1 (obecabtagene autoleucel) program demonstrated lower ADA rates compared to FMC63-based CARs.",
    "construct_name": "Obecabtagene autoleucel (AUTO1)",
    "target_antigen": "CD19",
    "scfv_clone": "CAT-19",
    "binding_affinity_kd": "1.2 nM",
    "heavy_chain_vregion": "Humanized VH based on VH3-23 germline acceptor framework. FMC63-derived CDRs grafted with key Vernier zone residues retained (positions 2, 27, 29, 30, 49). CDR-H3 retains the aromatic cluster from FMC63. Framework mutations at H47 and H93 restore VH/VL packing geometry.",
    "light_chain_vregion": "Humanized VL based on VK1-39 (O12) germline. CDR-L3 sequence preserved from FMC63. Back-mutations at L36 and L46 maintain the CDR-L1 canonical structure. In silico immunogenicity scoring (NetMHCIIpan) shows 60% reduction in predicted T-cell epitopes vs. murine FMC63.",
    "framework": "humanized IgG4 VH/VK (VH3-23/VK1-39 acceptor)",
    "species_origin": "humanized",
    "immunogenicity_risk": "low",
    "structural_notes": "Humanization reduced ADA incidence from ~5% to <1% in early clinical data. The 4-fold reduction in affinity (0.3 to 1.2 nM) relative to parental FMC63 does not impair in vivo efficacy. Fast-off rate CAR design (AUTO1) intentionally modulates tonic signaling to improve T-cell fitness."
  },
  {
    "id": "seq-21D4-005",
    "text_summary": "21D4 is a fully human anti-CD19 scFv isolated from a human phage display library. It binds a distinct epitope on CD19 with moderate affinity and shows no cross-reactivity with murine CD19. The fully human framework eliminates predicted immunogenicity concerns associated with murine or humanized scFvs, making it suitable for repeat dosing scenarios.",
    "construct_name": "Fully human CD19 CAR (21D4)",
    "target_antigen": "CD19",
    "scfv_clone": "21D4",
    "binding_affinity_kd": "4.8 nM",
    "heavy_chain_vregion": "Fully human VH from VH4-34 germline. CDR-H3 is 16 residues with a kinked base and extended tip structure. Framework 1 contains the characteristic VH4-34 AVY motif. CDR-H2 is unusually short (7 residues) but makes key contacts with CD19 Ig domain 1.",
    "light_chain_vregion": "Fully human VL lambda from VL3-21 germline. CDR-L3 (11 residues) is Ser-rich, forming hydrogen bonds with CD19 surface loops. Lambda framework provides higher intrinsic stability (Tm ~72C) compared to kappa light chains in scFv context.",
    "framework": "fully human IgG1 VH4-34/VL3-21",
    "species_origin": "fully_human",
    "immunogenicity_risk": "low",
    "structural_notes": "Phage display selection from Dyax human naive library. Epitope mapping reveals binding to CD19 residues 150-210 on Ig domain 1, non-overlapping with FMC63 epitope. May retain efficacy in CD19 epitope-loss relapse after FMC63-based therapy. Published in Bejcek et al., Cancer Immunol Res 2020."
  },
  {
    "id": "seq-LCARB38M-006",
    "text_summary": "LCAR-B38M (also designated CT103A) is the bispecific VHH tandem binder used in ciltacabtagene autoleucel (Carvykti), the first BCMA-targeted CAR-T approved by FDA. It employs two camelid-derived VHH domains (VHH1 and VHH2) targeting distinct epitopes on BCMA, conferring avidity-enhanced binding and resistance to antigen escape. This biparatopic design achieves an effective Kd of ~2 nM.",
    "construct_name": "Ciltacabtagene autoleucel (Carvykti)",
    "target_antigen": "BCMA (TNFRSF17)",
    "scfv_clone": "LCAR-B38M",
    "binding_affinity_kd": "2.0 nM",
    "heavy_chain_vregion": "VHH1: Camelid single-domain antibody (nanobody), 13-kDa, derived from llama immunization. Extended CDR3 (18 residues) forms a convex paratope typical of VHH domains. Binds BCMA epitope 1 near the APRIL/BAFF binding interface. VHH2: Second camelid nanobody targeting BCMA epitope 2 on the opposite face of the cysteine-rich domain.",
    "light_chain_vregion": "Not applicable. VHH nanobody format lacks light chain. The two VHH domains are connected by a flexible (G4S)4 linker allowing simultaneous engagement of two BCMA epitopes on the same or adjacent molecules.",
    "framework": "camelid VHH tandem (biparatopic)",
    "species_origin": "camelid",
    "immunogenicity_risk": "low",
    "structural_notes": "Biparatopic binding enables avidity effects, reducing effective off-rate by ~10-fold compared to monovalent VHH. BCMA epitope 1 overlaps with APRIL binding site; epitope 2 is membrane-proximal. The tandem VHH format (26 kDa total) is smaller than conventional scFv (27 kDa), reducing steric clashes. CARTITUDE-1 trial: 97.9% ORR in R/R myeloma (PMID:34407456)."
  },
  {
    "id": "seq-11D53-007",
    "text_summary": "Clone 11D5-3 is the murine anti-BCMA scFv used in idecabtagene vicleucel (Abecma), the first FDA-approved BCMA-directed CAR-T therapy. It binds a single epitope on BCMA with moderate affinity. The construct uses a 4-1BB costimulatory domain and lentiviral vector delivery. KarMMa trial demonstrated 73% ORR in heavily pretreated multiple myeloma.",
    "construct_name": "Idecabtagene vicleucel (Abecma)",
    "target_antigen": "BCMA (TNFRSF17)",
    "scfv_clone": "11D5-3",
    "binding_affinity_kd": "5.3 nM",
    "heavy_chain_vregion": "VH from murine hybridoma 11D5-3. CDR-H3 (11 residues) contains a Gly-Tyr-Asp motif that contacts the BCMA cysteine-rich domain. Framework regions are murine IgG2a germline. VH domain expresses well in scFv format with minimal aggregation.",
    "light_chain_vregion": "VL kappa with 9-residue CDR-L3. CDR-L1 (RASQSVSSSYLA, 12 residues) provides shape complementarity to the BCMA surface groove. Inter-domain disulfide (VH Cys44-VL Cys100) stabilizes the scFv interface in some engineered variants.",
    "framework": "murine IgG2a VH/VK",
    "species_origin": "murine",
    "immunogenicity_risk": "high",
    "structural_notes": "Monovalent BCMA binding contrasts with biparatopic Carvykti approach. Competition with soluble BCMA (sBCMA) shed from myeloma cells may reduce efficacy at high tumor burden. ADA rate of ~3% reported in KarMMa trial. Target cell density threshold for activation: ~1000 BCMA molecules per cell. PMID:33626253."
  },
  {
    "id": "seq-hBCMA-008",
    "text_summary": "CT053 is a humanized anti-BCMA scFv CAR-T developed by CARsgen Therapeutics. CDR grafting onto human acceptor frameworks reduced murine content to <5% of variable region residues. Phase I/II LUMMICAR-1 trial showed 88% ORR with reduced ADA formation compared to murine-derived BCMA CARs. The humanized format shows improved T-cell persistence in vivo.",
    "construct_name": "CT053 (humanized anti-BCMA CAR)",
    "target_antigen": "BCMA (TNFRSF17)",
    "scfv_clone": "CT053",
    "binding_affinity_kd": "3.7 nM",
    "heavy_chain_vregion": "Humanized VH on VH3-30 acceptor framework. CDRs derived from a murine anti-BCMA clone with key back-mutations at Vernier positions H47, H67, and H71 to maintain CDR loop conformations. CDR-H3 (13 residues) retains parental Asp-Tyr-Asp triad for BCMA binding.",
    "light_chain_vregion": "Humanized VL on VK3-20 acceptor framework. CDR-L3 (9 residues) with Gln-His-Phe-Trp motif. Back-mutations at positions L2 and L49 preserve VH/VL interface packing. Thermal stability improved over parental murine scFv (Tm increase from 58C to 65C).",
    "framework": "humanized IgG1 VH3-30/VK3-20",
    "species_origin": "humanized",
    "immunogenicity_risk": "low",
    "structural_notes": "LUMMICAR studies (NCT03975907). Humanization achieved through structure-guided CDR grafting using homology model. Key framework residues at the VH/VL interface were selected by computational design (Rosetta). Reduced tonic signaling compared to murine parental scFv based on CD69 expression in unstimulated CAR-T cells."
  },
  {
    "id": "seq-BCMApep-009",
    "text_summary": "BCMA-targeting designed ankyrin repeat protein (DARPin) represents a non-antibody binding scaffold approach for CAR-T therapy. The DARPin Bc1 module (14 kDa) binds BCMA with high specificity and is resistant to aggregation. Unlike scFvs, DARPins lack disulfide bonds and fold efficiently in the reducing intracellular environment, eliminating misfolding-driven tonic signaling.",
    "construct_name": "DARPin-BCMA CAR (Bc1)",
    "target_antigen": "BCMA (TNFRSF17)",
    "scfv_clone": "Bc1-DARPin",
    "binding_affinity_kd": "8.5 nM",
    "heavy_chain_vregion": "Not applicable. DARPin scaffold consists of 4 ankyrin repeat modules (N-cap, 2 internal repeats, C-cap) totaling 130 residues. Randomized positions in the internal repeats (6 residues per repeat) form the BCMA-binding paratope. No CDR equivalent; binding surface is a concave beta-turn/alpha-helix interface.",
    "light_chain_vregion": "Not applicable. DARPin is a single-domain scaffold with no light chain equivalent. The binding surface area (~850 A^2) is comparable to a conventional scFv paratope. Target recognition relies on shape complementarity rather than electrostatic interactions.",
    "framework": "designed ankyrin repeat protein (DARPin)",
    "species_origin": "fully_human",
    "immunogenicity_risk": "low",
    "structural_notes": "DARPin scaffold selected from synthetic libraries (>10^12 diversity) using ribosome display. No disulfide bonds eliminates aggregation-driven tonic signaling in CAR format. Thermostability: Tm >90C. Protease-resistant. Preclinical studies show equivalent tumor clearance to scFv-based BCMA CARs in NSG mouse models. Published by Molecular Partners/University of Pennsylvania collaboration."
  },
  {
    "id": "seq-m971-010",
    "text_summary": "m971 is a high-affinity anti-CD22 scFv derived from a human phage display library, developed at the NIH by Haso et al. It targets the membrane-proximal Ig domains 5-7 of CD22, achieving superior CAR-T activity compared to clones binding the distal domains. The construct has shown clinical efficacy in B-ALL patients who relapsed after CD19-directed therapy.",
    "construct_name": "Anti-CD22 CAR (m971)",
    "target_antigen": "CD22 (Siglec-2)",
    "scfv_clone": "m971",
    "binding_affinity_kd": "0.6 nM",
    "heavy_chain_vregion": "Fully human VH derived from phage display (Fv library). VH1-69 germline. CDR-H3 (19 residues) is unusually long, forming an extended beta-hairpin that inserts into a cleft between CD22 Ig domains 5 and 6. CDR-H2 contains a critical Arg that forms a salt bridge with CD22 Glu425.",
    "light_chain_vregion": "Fully human VL kappa from VK3-15 germline. CDR-L3 (9 residues) with Trp-Pro-Arg motif. The VL domain contributes approximately 40% of antigen contacts, primarily through CDR-L1 and CDR-L3 loops. VH/VL interface contains 4 conserved hydrophobic residues maintaining stable pairing.",
    "framework": "fully human IgG1 VH1-69/VK3-15",
    "species_origin": "fully_human",
    "immunogenicity_risk": "low",
    "structural_notes": "m971 binds CD22 Ig domains 5-7 (membrane-proximal), which is critical for CAR-T function. Clones targeting Ig domains 1-3 (e.g., HA22/RFB4) showed poor CAR activity despite high affinity. Epitope proximity to membrane improves immunological synapse formation. PMID:23207164 (Haso et al., Blood 2013). Clinical trial NCT02315612 at NCI."
  },
  {
    "id": "seq-m971v2-011",
    "text_summary": "An affinity-reduced variant of m971 (m971-L7) was engineered to test whether moderate affinity improves CAR-T persistence and reduces exhaustion. Site-directed mutagenesis at CDR-H3 position 100a (Tyr to Ala) reduced Kd from 0.6 nM to 15 nM while maintaining specificity. The reduced affinity variant showed improved in vivo persistence and comparable tumor control in preclinical models.",
    "construct_name": "Anti-CD22 CAR (m971-L7, affinity-reduced)",
    "target_antigen": "CD22 (Siglec-2)",
    "scfv_clone": "m971-L7",
    "binding_affinity_kd": "15 nM",
    "heavy_chain_vregion": "Modified VH from m971 with Y100aA mutation in CDR-H3. This removes a key aromatic contact with CD22, increasing the off-rate (koff) by ~25-fold while minimally affecting on-rate (kon). Framework and remaining CDR residues are identical to parental m971.",
    "light_chain_vregion": "Identical to parental m971 VL kappa. CDR-L3 Trp-Pro-Arg motif retained. No mutations in light chain. VL contributes unchanged binding contacts, but the overall complex stability is reduced by the VH mutation.",
    "framework": "fully human IgG1 VH1-69/VK3-15 (affinity-modified)",
    "species_origin": "fully_human",
    "immunogenicity_risk": "low",
    "structural_notes": "Affinity tuning demonstrates that ultra-high affinity (sub-nM) is not required for CAR-T efficacy and may promote T-cell exhaustion through sustained signaling. The optimal affinity window for CD22 CARs appears to be 5-50 nM. Reduced-affinity CARs show lower PD-1/LAG-3 expression and increased central memory T-cell differentiation."
  },
  {
    "id": "seq-CD19CD22-012",
    "text_summary": "Tandem CD19/CD22 bispecific CAR uses FMC63 anti-CD19 and m971 anti-CD22 scFvs connected in a single bivalent CAR molecule. This design addresses antigen escape, as CD19 loss occurs in 30-60% of patients relapsing after CD19 CAR-T therapy. The tandem construct signals through either antigen alone and shows synergistic activation when both are engaged simultaneously.",
    "construct_name": "CD19/CD22 tandem CAR (FMC63-m971)",
    "target_antigen": "CD19 + CD22 (dual)",
    "scfv_clone": "FMC63 + m971 (tandem)",
    "binding_affinity_kd": "0.3 nM (CD19), 0.6 nM (CD22)",
    "heavy_chain_vregion": "FMC63 VH (distal position) and m971 VH (proximal position) arranged in tandem. The distal FMC63 VH is connected to FMC63 VL via (G4S)3 linker, then a rigid helical linker (EAAAK)3 connects to m971 VH-(G4S)3-VL. Total extracellular binding domain ~54 kDa.",
    "light_chain_vregion": "FMC63 VL kappa and m971 VL kappa in respective scFv modules. Each VL is paired with its cognate VH by (G4S)3 flexible linker. Chain mispairing between the two scFv modules is minimized by the rigid inter-scFv linker and validated by SEC showing monodisperse CAR protein.",
    "framework": "murine IgG1 (FMC63) + fully human IgG1 (m971) tandem",
    "species_origin": "murine",
    "immunogenicity_risk": "moderate",
    "structural_notes": "Tandem orientation (CD19 distal, CD22 proximal) outperformed reverse orientation in cytotoxicity assays. OR-gate logic: activation occurs if either CD19 or CD22 is present. Synergistic activation with dual antigen engagement shows ~3-fold increase in IFN-gamma production. Clinical trial NCT03241940 at Stanford. Addresses CD19-negative relapse seen in 30-60% of post-CART failures."
  },
  {
    "id": "seq-CD19BCMA-013",
    "text_summary": "A CD19/BCMA bispecific CAR construct targets both B-cell lineage marker CD19 and plasma cell marker BCMA simultaneously. This approach enables broader coverage of B-cell malignancies from early B-cells to terminally differentiated plasma cells. The bispecific design uses humanized CD19 scFv (CAT-19 derivative) paired with LCAR-B38M-derived VHH for BCMA.",
    "construct_name": "CD19/BCMA bispecific CAR (GC012F)",
    "target_antigen": "CD19 + BCMA (dual)",
    "scfv_clone": "humanized CD19 scFv + BCMA VHH (GC012F)",
    "binding_affinity_kd": "1.5 nM (CD19), 2.8 nM (BCMA)",
    "heavy_chain_vregion": "CD19 binder: humanized scFv VH on VH3-23 framework. BCMA binder: single camelid VHH domain (15 kDa) with extended CDR3 (17 residues). The VHH is positioned proximal to membrane, CD19 scFv is distal. Total extracellular domain ~42 kDa.",
    "light_chain_vregion": "CD19 binder: humanized VL kappa with CDR-grafted framework. BCMA VHH: no light chain required (single-domain format). The asymmetric binding module sizes (scFv 27 kDa + VHH 15 kDa) create a compact bispecific with reduced inter-domain steric interference.",
    "framework": "humanized IgG1 VH/VK (CD19) + camelid VHH (BCMA)",
    "species_origin": "humanized",
    "immunogenicity_risk": "low",
    "structural_notes": "GC012F (Gracell/AbbVie) showed 100% MRD-negative rate in R/R myeloma (ASCO 2022). Dual targeting reduces antigen escape risk. The mixed scFv/VHH architecture avoids chain mispairing issues of dual-scFv designs. Lentiviral vector delivery. 4-1BB costimulatory domain. Clinical trial NCT04236011."
  },
  {
    "id": "seq-FRP5-014",
    "text_summary": "FRP5 is a humanized anti-HER2 scFv used in CAR-T constructs targeting HER2-positive solid tumors including glioblastoma, sarcoma, and breast cancer. It binds domain IV of HER2 ECD with moderate affinity, distinct from the trastuzumab epitope (domain IV/II junction). CAR-T cells bearing FRP5 have been evaluated in GBM clinical trials with locoregional delivery.",
    "construct_name": "Anti-HER2 CAR (FRP5)",
    "target_antigen": "HER2 (ErbB2)",
    "scfv_clone": "FRP5",
    "binding_affinity_kd": "3.2 nM",
    "heavy_chain_vregion": "Humanized VH from murine parental antibody FRP5. VH3-23 acceptor framework with 6 back-mutations to preserve CDR conformations. CDR-H3 (12 residues) forms a flat paratope complementary to the convex HER2 domain IV surface. CDR-H2 Tyr residue provides a critical hydrogen bond to HER2 Asp560.",
    "light_chain_vregion": "Humanized VL kappa on VK1-39 framework. CDR-L1 (11 residues) and CDR-L3 (9 residues) form a groove that accommodates HER2 loop 557-564. Humanization preserved 7 key antigen-contact residues identified by alanine scanning mutagenesis.",
    "framework": "humanized IgG1 VH3-23/VK1-39",
    "species_origin": "humanized",
    "immunogenicity_risk": "low",
    "structural_notes": "FRP5 binds HER2 domain IV, which is membrane-proximal and distinct from trastuzumab (domain IV/II junction) and pertuzumab (domain II) epitopes. Critical safety consideration: HER2 expression on cardiac myocytes requires careful dose titration. Intracranial delivery for GBM bypasses on-target/off-tumor cardiac toxicity. Clinical trials NCT01109095 (Ahmed et al., HER2-GBM). PMID:25561716."
  },
  {
    "id": "seq-SS1-015",
    "text_summary": "SS1 is a high-affinity anti-mesothelin scFv derived from the SS1P immunotoxin, originally developed at the NCI by Ira Pastan. Mesothelin is overexpressed in mesothelioma, pancreatic, and ovarian cancers. The SS1 scFv-based CAR has been tested in multiple clinical trials, though efficacy has been limited by the immunosuppressive solid tumor microenvironment and on-target/off-tumor expression in pleural mesothelial cells.",
    "construct_name": "Anti-mesothelin CAR (SS1)",
    "target_antigen": "Mesothelin (MSLN)",
    "scfv_clone": "SS1",
    "binding_affinity_kd": "11 nM",
    "heavy_chain_vregion": "Murine VH from SS1 hybridoma. CDR-H3 (10 residues) contains a Tyr-Gly-Tyr motif that contacts mesothelin region III (residues 296-390). VH contributes ~55% of binding energy. Framework is murine IgG1 germline. An engineered disulfide (VH44-VL100) variant shows improved stability.",
    "light_chain_vregion": "Murine VL kappa from SS1. CDR-L3 (8 residues) with Gln-Gln-Tyr-Asn motif. The VL domain contacts mesothelin primarily through CDR-L1 and framework 3 residues. SPR kinetics: kon = 2.1 x 10^5 M^-1s^-1, koff = 2.3 x 10^-3 s^-1.",
    "framework": "murine IgG1 VH/VK",
    "species_origin": "murine",
    "immunogenicity_risk": "high",
    "structural_notes": "SS1 competes with CA-125/MUC16 for mesothelin binding, as their epitopes partially overlap. This is therapeutically relevant since mesothelin-MUC16 interaction promotes peritoneal metastasis. Humanized variant (hSS1) developed to reduce immunogenicity. Combined with PD-1 checkpoint inhibition to overcome solid tumor resistance. Clinical trials at UPenn (NCT02159716, Beatty et al.)."
  },
  {
    "id": "seq-14g2a-016",
    "text_summary": "14g2a is a murine anti-GD2 scFv used in CAR-T constructs targeting neuroblastoma, melanoma, and other GD2-expressing solid tumors. GD2 is a disialoganglioside with restricted expression in normal tissues (peripheral nerves, brain). The 14g2a-based CAR (GD2-CAR) has shown clinical activity in neuroblastoma, though pain neuropathy from on-target/off-tumor binding to peripheral nerves is a dose-limiting toxicity.",
    "construct_name": "Anti-GD2 CAR (14g2a)",
    "target_antigen": "GD2 (disialoganglioside)",
    "scfv_clone": "14g2a",
    "binding_affinity_kd": "2.1 nM",
    "heavy_chain_vregion": "Murine VH from hybridoma 14g2a (IgG2a isotype). CDR-H3 (8 residues) is relatively short, consistent with carbohydrate antigen recognition. The VH paratope forms a shallow groove accommodating the GD2 glycolipid headgroup (NeuAc-NeuAc-Gal-GalNAc). CDR-H2 Arg provides critical electrostatic contact with GD2 sialic acid carboxylates.",
    "light_chain_vregion": "Murine VL kappa. CDR-L3 (9 residues) contributes to the carbohydrate-binding groove. CDR-L1 Asn forms hydrogen bonds with GD2 galactose hydroxyl groups. The shallow binding pocket typical of anti-carbohydrate antibodies results in faster off-rate compared to protein-targeting scFvs.",
    "framework": "murine IgG2a VH/VK",
    "species_origin": "murine",
    "immunogenicity_risk": "high",
    "structural_notes": "GD2 is a glycolipid, not a protein antigen. CAR engagement is unique because GD2 cannot be endocytosed/downregulated like protein antigens. On-target/off-tumor pain neuropathy from GD2 on peripheral nerves is managed with analgesics. An E101K mutation in CDR-H3 (hu3F8-based variant) enhances affinity 10-fold. Clinical trial NCT02107963 at Baylor (Heczey et al., Mol Ther 2017, PMID:28434751)."
  },
  {
    "id": "seq-NbCD19-017",
    "text_summary": "Anti-CD19 VHH nanobody Nb1 is a single-domain antibody format derived from an immunized alpaca. At 15 kDa, the nanobody is roughly half the size of a conventional scFv, enabling higher surface density on CAR-T cells and improved access to sterically hindered epitopes. The nanobody CAR format eliminates VH/VL misfolding and tonic signaling issues associated with scFv-based CARs.",
    "construct_name": "Anti-CD19 nanobody CAR (Nb1-CD19)",
    "target_antigen": "CD19",
    "scfv_clone": "Nb1-CD19 (VHH)",
    "binding_affinity_kd": "5.4 nM",
    "heavy_chain_vregion": "Alpaca-derived VHH (nanobody) with hallmark camelid substitutions at positions 37 (Phe>Gly), 44 (Gly>Glu), 45 (Leu>Arg), and 47 (Trp>Gly) that eliminate the VH/VL interface requirement. CDR3 is 18 residues long, forming a finger-like loop that penetrates a CD19 surface cavity inaccessible to conventional scFvs.",
    "light_chain_vregion": "Not applicable. VHH nanobody is a single-domain format with no light chain. The former VL interface is solvent-exposed and replaced by hydrophilic residues, ensuring solubility and preventing aggregation. Single-domain format enables ~2-fold higher CAR surface density compared to scFv-based CARs.",
    "framework": "camelid VHH (alpaca-derived)",
    "species_origin": "camelid",
    "immunogenicity_risk": "low",
    "structural_notes": "Nanobody CARs show reduced tonic signaling (lower basal CD3-zeta phosphorylation) due to absence of VH/VL misfolding. Higher CAR surface density (~50,000 vs ~25,000 molecules/cell) enhances sensitivity to low-antigen-density targets. Nanobody CDR3 accesses cryptic epitopes through its elongated loop structure. Humanization of VHH framework reduces immunogenicity risk. Published by Iri-Sofla et al."
  },
  {
    "id": "seq-DARPin-018",
    "text_summary": "An anti-HER2 designed ankyrin repeat protein (DARPin) G3 was incorporated into a CAR-T construct as an alternative to scFv-based binding. DARPins are ~14 kDa synthetic proteins with high thermal stability (Tm >90C) and no disulfide bonds, enabling efficient folding in the reducing cytoplasmic environment during CAR biosynthesis. The G3 DARPin shows high specificity for HER2 domain I.",
    "construct_name": "Anti-HER2 DARPin CAR (G3)",
    "target_antigen": "HER2 (ErbB2)",
    "scfv_clone": "G3-DARPin",
    "binding_affinity_kd": "0.09 nM",
    "heavy_chain_vregion": "Not applicable. DARPin G3 consists of N-capping repeat, 3 internal ankyrin repeats (33 residues each), and C-capping repeat. Each internal repeat has a beta-turn and alpha-helix. Randomized paratope positions (7 per repeat, 21 total) form a concave binding surface recognizing HER2 domain I.",
    "light_chain_vregion": "Not applicable. Single-domain scaffold. The concave binding surface (26 x 14 A) buries ~1100 A^2 upon HER2 complex formation, larger than typical scFv paratopes (~800 A^2). Binding is predominantly hydrophobic with critical Phe and Leu residues at positions 5, 12, and 26 of repeat 2.",
    "framework": "designed ankyrin repeat protein (DARPin, 3-repeat)",
    "species_origin": "fully_human",
    "immunogenicity_risk": "low",
    "structural_notes": "DARPin G3 (PDB: 4HRL) binds HER2 domain I, distinct from trastuzumab (domain IV) and FRP5 (domain IV) epitopes. Ultra-high affinity (90 pM) may require affinity tuning for optimal CAR function. No disulfide bonds eliminates aggregation during ER processing. Preclinical studies show equivalent anti-tumor activity to trastuzumab-scFv CAR with improved CAR surface expression. Pluckthun lab, University of Zurich."
  },
  {
    "id": "seq-Centyrin-019",
    "text_summary": "Centyrins are synthetic binding proteins based on the human tenascin type III fibronectin domain (FN3) scaffold. An anti-BCMA Centyrin (P0301) was developed as a non-immunoglobulin CAR binder for multiple myeloma. The 10-kDa Centyrin lacks disulfide bonds and shows exceptional thermostability. Its small size and human origin minimize immunogenicity while maintaining nanomolar target binding.",
    "construct_name": "Anti-BCMA Centyrin CAR (P0301)",
    "target_antigen": "BCMA (TNFRSF17)",
    "scfv_clone": "P0301-Centyrin",
    "binding_affinity_kd": "6.2 nM",
    "heavy_chain_vregion": "Not applicable. Centyrin scaffold based on human tenascin-C FN3 domain (94 residues). Three surface loops (BC, DE, FG) are diversified to create the BCMA-binding paratope, analogous to antibody CDR loops. BC loop (8 residues) and FG loop (10 residues) provide primary antigen contacts. Beta-sandwich core provides rigid scaffolding.",
    "light_chain_vregion": "Not applicable. Single-domain scaffold derived from human protein (tenascin-C). The binding surface is composed of loops on one face of the beta-sandwich, burying ~750 A^2 on BCMA. Selection from yeast surface display library (>10^10 diversity) ensured high specificity with no cross-reactivity to related TNF receptor family members (TACI, BAFFR).",
    "framework": "Centyrin (human tenascin FN3 scaffold)",
    "species_origin": "fully_human",
    "immunogenicity_risk": "low",
    "structural_notes": "Centyrins (Janssen/Aro Biotherapeutics) represent the smallest non-immunoglobulin CAR binder format at 10 kDa. No disulfide bonds; folds efficiently in reducing environment. Tm >80C. Monodisperse by SEC with no aggregation at 10 mg/mL. Preclinical data shows reduced tonic signaling (50% lower baseline pCD3z) vs. scFv-based BCMA CARs. Compatible with both 4-1BB and CD28 costimulatory domains."
  },
  {
    "id": "seq-AffTune-020",
    "text_summary": "Systematic affinity engineering of the FMC63 anti-CD19 scFv revealed an optimal binding affinity window of 1-10 nM for CAR-T therapeutic function. An affinity library spanning Kd 0.1-1000 nM was generated by CDR-H3 mutagenesis. Ultra-high affinity variants (<0.1 nM) showed increased tonic signaling and T-cell exhaustion, while variants >100 nM failed to trigger cytotoxicity against CD19-low targets.",
    "construct_name": "FMC63 affinity library (CAR optimization panel)",
    "target_antigen": "CD19",
    "scfv_clone": "FMC63 affinity variants (FMC63-H3lib)",
    "binding_affinity_kd": "0.1-1000 nM (library range); optimal 1-10 nM",
    "heavy_chain_vregion": "FMC63 VH with CDR-H3 saturation mutagenesis at positions 95, 97, 98, 100, and 100a. 32 variants characterized by SPR. Key findings: Y100aF mutation reduces Kd 3-fold (1.0 nM); S97A reduces 10-fold (3.2 nM); double mutant Y100aF/S97A achieves 8.5 nM. All variants retain specificity for CD19.",
    "light_chain_vregion": "FMC63 VL held constant across the affinity library. VL CDR-L3 mutations were also tested (separate library) but showed narrower affinity range (0.2-15 nM), confirming VH CDR-H3 as the primary affinity determinant. VL framework stability was unaffected by VH CDR-H3 mutations (Tm variation <2C).",
    "framework": "murine IgG1 VH/VK (FMC63 variants)",
    "species_origin": "murine",
    "immunogenicity_risk": "moderate",
    "structural_notes": "Optimal CAR-T affinity window: 1-10 nM for CD19. Sub-nanomolar binders show increased PD-1/TIM-3 co-expression (exhaustion markers). >100 nM binders fail against CD19-low relapse variants (~200 molecules/cell). The 1-10 nM window balances sensitivity (ability to detect low antigen) with T-cell fitness (avoidance of exhaustion). Consistent with findings for other antigens (HER2: 1-50 nM; BCMA: 2-20 nM). Liu et al., Cancer Cell 2021."
  }
]
